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Abstract
Background: Recruitment and retention of participants in randomised controlled trials (RCTs) is a key determinant
of success but is challenging. Trialists and UK Clinical Research Collaboration (UKCRC) Clinical Trials Units (CTUs) are
increasingly exploring the use of digital tools to identify, recruit and retain participants. The aim of this UK National
Institute for Health Research (NIHR) study was to identify what digital tools are currently used by CTUs and
understand the performance characteristics required to be judged useful.
Methods: A scoping of searches (and a survey with NIHR funding staff), a survey with all 52 UKCRC CTUs and 16
qualitative interviews were conducted with five stakeholder groups including trialists within CTUs, funders and
research participants. A purposive sampling approach was used to conduct the qualitative interviews during
March–June 2018. Qualitative data were analysed using a content analysis and inductive approach.
Results: Responses from 24 (46%) CTUs identified that database-screening tools were the most widely used digital tool
for recruitment, with the majority being considered effective. The reason (and to whom) these tools were considered
effective was in identifying potential participants (for both Site staff and CTU staff) and reaching recruitment target (for
CTU staff/CI). Fewer retention tools were used, with short message service (SMS) or email reminders to participants being
the most reported. The qualitative interviews revealed five themes across all groups: ‘security and transparency’; ‘inclusivity
and engagement’; ‘human interaction’; ‘obstacles and risks’; and ‘potential benefits’. There was a high level of stakeholder
acceptance of the use of digital tools to support trials, despite the lack of evidence to support them over more traditional
techniques. Certain differences and similarities between stakeholder groups demonstrated the complexity and challenges
of using digital tools for recruiting and retaining research participants.
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Conclusions: Our studies identified a range of digital tools in use in recruitment and retention of RCTs, despite the lack of
high-quality evidence to support their use. Understanding the type of digital tools in use to support recruitment and
retention will help to inform funders and the wider research community about their value and relevance for future RCTs.
Consideration of further focused digital tool reviews and primary research will help to reduce gaps in the evidence base.
Keywords: Digital tool, Participant recruitment, Participant retention, Qualitative, Survey, Clinical trials unit
Background
Recruitment of participants to, and their retention in,
randomised controlled trials (RCTs) is a key determinant
of research efficiency, but it can be challenging [1]. Re-
views of clinical trials funded by the UK Medical Re-
search Council (MRC) and the National Institute for
Health Research (NIHR) Health Technology Assessment
(HTA) programme [2] have shown that the proportion
of trials achieving their original recruitment target was
in the range of 31%–56%, and 79% of trials achieving at
least 80% of the final target sample size (119/151, trials
reporting from 2004 to April 2016) [3, 4]. Although the
literature seems to suggest that there have been im-
provements over time, a recent study found that 44% of
selected trials failed to reach their target [3, 5, 6]. Des-
pite the vast amount of literature on strategies to im-
prove recruitment and retention in clinical trials, the
quality of the evidence is lacking [5–10]. The recently
updated Cochrane Review on strategies to improve re-
cruitment to RCTs found only three studies with a high
Grading of Recommendations Assessment, Development
and Evaluation (GRADE) rated evidence [6]. Given the
lack of high-quality evidence and certainty around
resource-intensive techniques to improve recruitment
and retention, trialists and Clinical Trials Units (CTUs)
are increasingly exploring the value of digital tools as a
more viable option to identify, recruit and retain partici-
pants. Existing literature investigating the use of digital
technology/tools for recruitment to and retention in
clinical trials has mainly focused on:
 Eligibility: searches and interactive medical record
tools to support clinicians screening participants
[11];
 Recruitment: trial websites, social media and email
campaigns to engage with the broader public [12–15];
 Retention: emails, interactive websites, text messages or
apps to retain participants enrolled in trials and help
them adhere to the trial intervention [9, 10, 16–18].
In theory, the use of digital tools should reduce re-
search costs and speed up the delivery of results, im-
prove recruitment rates and reduce the recruitment of
ineligible participants (around 6% in one study [11]).
However, selecting an appropriate digital tool for a trial
is challenging because few have been evaluated rigor-
ously. More challenging perhaps is the use of different
success metrics to understand how and where digital
tools add value to the recruitment and retention of par-
ticipants in trials, e.g. reduced screening time, improved
coverage of recruitment or percentage of participants re-
cruited. Given the lack of evidence, there is a need to ex-
plore which success metrics are useful to determine
which digital tools (and what features of the tools) are
most relevant to stakeholders and encourage a wider up-
take of the use of effective digital tools.
One systematic review, on databases to improve trial
recruitment, located only nine studies using reasonably
robust methods out of the 101 eligible studies [19]. It
concluded that databases could reduce the time taken to
screen participants, improve participant coverage and
actual recruitment rates by between 14%, though four of
the five studies making these measurements used an un-
controlled before–after design and the fifth was con-
founded. This suggests a need to assemble, map and
critically appraise the evidence base for these digital
tools to determine their value and benefit for improving
recruitment and retention rates. Only then can we confi-
dently advise on the wider use of such digital tools by
trialists or on the need for further primary research.
The aim of this study was to answer the following two
questions: (1) What are the digital tools that could help
identify, recruit or retain participants in trials are used
in UK CTUs? and (2) What performance characteristics
do trialists and CTUs require of digital tools for them to
be judged useful?
Methods
The research reported here was part of a broader NIHR-
funded project ‘User-focused research to identify the
benefits of innovative digital recruitment and retention’.
There were three phases in the main study:
Phase 1: Scoping of searches and a survey of NIHR
funder staff to determine what digital tools are
currently being used by funded clinical trials.
Phase 2: (1) A survey of CTUs on their experiences of
digital tools; (2) the development of a logic model to
help classify the digital tools into generic categories and
identify potential outcome measures for Phase 3 and
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future primary studies; (3) qualitative interviews with
key stakeholders to identify the characteristics of digital
tools that they would judge useful and potential
disadvantages of these tools.
Phase 3: A systematic mapping exercise to identify and
describe studies of the effectiveness and accuracy of digital
tools for recruitment and/or retention in RCTs [20].
This paper reports on the Phase 1 and Phase 2 survey
of CTUs and qualitative interviews. The other aspects of
this project have been submitted elsewhere [20].
To ensure quality assurance, a Project Management
Team and Project Board were created. The role of the
Project Management Team included the day-to-day run-
ning of the project and the review and sign-off of all
study documentation and analysis. The role of the Pro-
ject Board was to oversee the work of the Project Man-
agement Team to ensure delivery of the project and
adherence to the ethically approved research methods.
Phase 1: Scoping of searches and a survey of funder staff
A scoping exercise was conducted to explore the range
of digital tools used within trials to increase the effi-
ciency of recruitment and retention in trials. This con-
sisted of a review of published and grey literature
(PubMed and Google Scholar) using a variation of key
words and phrases:
– Digital / tools to improve study recruitment /
retention in trials / clinical trials
– Digital platforms for trial recruitment
– Retention in research studies / digital platforms in use
To avoid duplication with the systematic mapping ex-
ercise conducted in Phase 3, this was limited to: Recruit-
ment; Retention; Clinical trials; and Study design. A
snowball approach was used to retrieve relevant litera-
ture. The online search was conducted in December
2017 and the results were shared with the project team
to inform the content of the CTU survey questions and
qualitative interview frameworks. The scoping exercise
was not systematic (systematically applied a search cri-
teria or systematic methods for replication). The purpose
of the literature review was to inform the CTU survey
and the qualitative interviews.
An online survey (using Google forms) was sent to
NIHR Evaluation, Trials and Studies Coordinating Centre
(NETSCC) research management staff in February 2018
to understand how many funded trials have used or are
using digital tools across four of the NIHR research pro-
grammes (Efficacy and Mechanism Evaluation [EME],
Health Services and Delivery Research [HSDR], Health
Technology Assessment [HTA] and Public Health Re-
search [PHR]). Examples of relevant digital tools were
provided to help inform the research manager’s review of
their portfolio of funded research projects (Additional file 1).
A reminder was sent to NETSCC staff and the deadline
was extended by 1 week with the option of discussing the
survey with a member of the research team.
Phase 2: CTU survey
Preliminary findings from Phase 1 were used to inform
and develop the CTU survey. This survey (SurveyMon-
key) was sent to the Directors of all UK Clinical Re-
search Collaboration (UKCRC)-registered CTUs, via
email circulation from the UKCRC administrator, during
March–May 2018. The Directors were asked to dissem-
inate this to the most relevant CTU staff member (e.g.
Head of Trial Management / Operations). A webinar
was conducted during March 2018 to help explain the
nature of these digital tools and increase response and
completion rate and a follow-up reminder email was
sent to all participating CTUs via the same mechanism
as the initial invitation. A definition of a digital tool and
examples of digital tools were provided and CTUs were
asked to list up to five recruitment tools and five reten-
tion tools they have experience of, and then to expand
on up to two tools that had impressed them within each
category and about one of either kind that they have ex-
perienced problems with. The questions focused on the
performance characteristics related to the digital tools
that are currently being used to identify, recruit and re-
tain participant within CTU trials. The salient perform-
ance characteristics were: recruitment barrier for which
the tool is a solution; its source (commercial, in-house,
academic); the study context (was there a specific disease
area, type of study and population). Costs were specific-
ally not asked for due to the perceived difficulty in an-
swering this questions; however, ease of configuration
was asked (i.e. did an expert need to build it or could
the CTU do it themselves). The last questions focused
on estimated effectiveness and reason for and to whom
(Additional file 2). The survey results were categorised,
discussed and verified with the project team.
Phase 2: Qualitative interviews
The sampling of participants was purposive due to the
availability of resources, participant availability and the
number of participants required to reach data saturation
(the project team agreed on three participants per stake-
holder group and if additional participants were required
they would be approached and invited on a case-by-case
basis). The project team were responsible for the eligibil-
ity criteria who work in clinical trials settings, ethics
committee representatives and researchers from the
NIHR. The potential sample of participants were chosen
on a case-by-case basis (in agreement and consensus
with project team members) from a broad range of
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professional backgrounds with diverse experiences of re-
cruitment and/or retention in clinical trials. This sam-
pling approach identified research professionals with
appropriate trial recruitment experience based on those
known to the project team members and recommenda-
tions from the Principal Investigator. A list of contact
details for each stakeholder group for eligible partici-
pants was developed which included staff in medical re-
search funding organisations and charities, individuals
working on trials in primary and secondary care, and re-
search participant representatives (Table 1). For the tri-
alists group, those who participated in the CTU survey
were asked if they would be willing to participate in an
interview.
A potential sample of participants were selected before
sending out an invitation by email to participate. If any
potential participants declined the invitation, further
participants were chosen from the groups that were
identified at the start of the sampling process.
The participant representatives were chosen through
existing local patient groups associated with the local
CTU (Southampton). The initial plan was to engage with
participant representatives through focus groups but we
were unable to recruit the appropriate number of partic-
ipants to take part in the time period allowed to conduct
these (none of the participants agreed to participate in
the focus group). As a result, we offered telephone inter-
views as an alternative and we were able to recruit the
proposed number of participant representatives (n = 4)
(as outlined in the ethics application if focus groups
were not feasible, interviews will be offered to the par-
ticipant representatives). The sample method applied to
the stakeholder groups were therefore used for the par-
ticipant representative group.
The decision to approach the agreed sampling groups
was based upon consensus from discussions with the
project team to provide sufficient data to answer the re-
search question and provide wide coverage of the use of
digital tools. All potential participant groups, including
the research participant representatives responded to an
‘invitation to volunteer’ from the study researcher
through the CTU (email from the current project Princi-
pal Investigator). A participant information sheet was
sent with the invitation, asking the recipients of these in-
vitations to approach the researcher directly via email or
phone to indicate their interest in participating in an
interview. They were invited via email to participate in
an interview at a mutually convenient time and date.
Email reminders were sent after initial contact of the ori-
ginal invitation.
Participants engaged in a 45-min, semi-structured tele-
phone interview (Additional file 3). The professional
group were not specifically asked about the acceptance
of digital tools and the participant representative stake-
holder group were not specifically asked about the
intended outcomes, participant perspective or their
awareness of the evidence. The interview framework was
developed from the CTU survey findings, and interviews
were undertaken during May–June 2018. Each partici-
pant’s identity remained anonymous in all reports and
identifying data were password-protected and only ac-
cessible by the research team (outlined in the General
Data Protection Regulation [GDPR] May 2018).
An inductive approach was used to establish clear
links between the interview framework for data collec-
tion and the summary of findings from the raw data (i.e.
the interviews). Two researchers conducted dual coding
for quality assurance measures. Data saturation was
reached when no new constructs, categories or themes
emerged from the interview data. A content analysis was
conducted to provide a summary of the interview data.
Both processes were conducted using Microsoft Excel
2016 (Microsoft Corporation). The theoretical frame-
work for the interviews and schedules are available
(Additional files 3 and 4, respectively). Ethics approval
was granted by the Faculty of Medicine Ethics Commit-
tee, University of Southampton (Submission Number
32140) and the qualitative study was conducted to pro-
vide the ‘Outcomes’ and ‘Methodology’ of the PICO-M
(Population, Intervention, Comparator and Outcomes
Methodology) that shaped the systematic mapping exer-
cise and the study eligibility criteria.
Table 1 Stakeholders for qualitative interviews
Stakeholder groups
(number of participants)
Example of the type of roles held Eligibility criteria
(involvement in one or more of)
Trialists in CTUs (n = 3) in primary/secondary care Trialists and recruiters Trial recruitment
Management of trials (CTU staff)
Research practitioners in primary care (n = 3) Principal Investigators Leading funding applications
Research funding bodies (n = 3) Funding committee members / Charities Contribute to decision-making of funding allocation
from charities or NIHR
Ethics committees and Health Research
Authority (n = 3)
Ethics committee members Contribute to decision-making on research ethics
Research participant/patient representatives (n = 4) Research participant representatives Experience of participating in trials
CTU Clinical Trials Unit, NIHR National Institute for Health Research
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Results
Phase 1: Scoping of searches and a survey of funder staff
The scoping exercise revealed 46 examples of digital tools,
approaches or services: 23 online tools and applications;
16 clinical trial companies offering recruitment and reten-
tion services; and seven online forums or companies facili-
tating patient involvement. The preliminary survey was
sent to all 28 NETSCC Research Managers in February
2018. Thirteen (46%) staff completed the survey, yielding
26 examples of NIHR-funded trials using digital tools (ei-
ther for recruitment or retention; Table 2) across four
NIHR funding programmes (Table 3). Only a limited
number of trials provided a detailed account of the digital
tools used to help enhance the recruitment and/or reten-
tion of participants.
Phase 2: CTU survey
Twenty-four (46%) of 52 UKCRC CTUs responded to the
survey; 6 (25%) stated no prior tool use and 18 (75%) re-
ported five main areas of digital tool experience in recruit-
ment (Table 4) and retention (Table 5). In the 24
responses, 41 recruitment and 29 retention tools were men-
tioned, and CTUs provided detailed answers for 22 recruit-
ment tools (Table 6) and 15 retention tools (Table 7). The
most frequently mentioned tools were related to database
screening tools (e.g. Clinical Practice Research Datalink
[CPRD] and in-house built screening tools (e.g. Medical In-
formation Systems [EMIS]) (19/41, 46%). Of these 19 data-
base screening tools, 10 (45%) responders provided
additional information, of which 7 (70%) respondents felt
these database screening tools were the most effective. The
reason (and to whom) these tools were considered effective
was in identifying potential participants (for both Site staff
and CTU staff) and reaching recruitment target (for CTU
staff/CI). The reasons for using these tools and most fre-
quently mentioned barriers were to identify patients
quicker and thus save time, poor record keeping, reminders
to recruit and so on (6/10, 60%). Other performance char-
acteristics of these tools were: they were either commercial
(4/10, 40%) or built in-house (5/10, 50%) and were mainly
used across all disease areas (6/10, 60%); they were not spe-
cific to the needs of any care group (e.g. children, frail,
adults with learning disabilities, etc.) (9/10, 90%); and for all
study types (7/10, 70%). To configure these tools, an expert
was required in most cases (7/10, 70%). Although social
media was only mentioned by 6/22 (27%) responders, and
was the most frequently mentioned tool for ‘increasing trial
reach to participants’ (5/6, 83%), the estimated effectiveness
varied considerably, with only 17% stating ‘very effective’
(1/6).
Fewer retention tools were mentioned by the re-
sponders, with almost half reporting the use of SMS/
email reminders (17/29, 59%) and most CTUs choosing
to expand on the use of SMS/email reminders than any
other tool (10/15, 67%). The majority of the SMS/email
reminder programmes were developed in-house and be-
spoke (7/10, 70%), used for more than one study (9/10,
90%) and required an expert to develop the tool (7/10,
70%). However, the certainty surrounding effectiveness
varied and only one CTU stated their tool to be very ef-
fective (10%).
No CTU mentioned a tool that had caused problems
for recruitment or retention.
Table 2 Breakdown of the type of NIHR funding schemes











Themed call 1 (3.9)
EME Efficacy and Mechanisms Evaluation, HSDR Health Service and Delivery
Research, HTA Health Technology Assessment, NIHR National Institute for
Health Research, PHR Public Health Research
Table 4 Number of digital tools, by category that CTUs
mentioned they have experience of in relation to recruitment
(including identification)
Recruitment tools n (%)
Database tool (CPRD - Clinical Practice Research Datalink, in-
house built tool, disease registry)
19
(46)
Social media (e.g. Facebook, Twitter, YouTube) 11(27)
Trial websites 7 (17)
ISRCTN, clinicaltrials.gov 3 (7)
Other – in-house 1 (2)
CTU Clinical Trials Unit, CPRD Clinical Practice Research Datalink
Table 3 Types of digital approaches used in NIHR studies from
funding staff (multi-responses)
Example of digital tools used n (%)
Social media (e.g. Facebook, Twitter) 6 (23.1)
Text messaging 6 (23.1)
Online project websites 6 (23.1)
Named online services (e.g. Quintet) 3 (11.5)
Software / Apps (e.g. bespoke for intervention
such as StopApp digital intervention or
unnamed digital software platform reported)
4 (15.4)
Limited information reported 5 (19.2)
NIHR National Institute for Health Research
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Table 8 provides a list of potential digital tools to sup-
port recruitment and retention tasks that was developed
from the survey results.
Phase 2: Qualitative interviews
Sixteen interviews were conducted across five stake-
holder groups during a 2-month period (May–June
2018). The content analysis based on the interview
framework topics (Table 9) revealed that the two most
commonly discussed areas across all stakeholders were
the barriers, challenges and benefits of using digital
tools. There were some necessary differences between
the interview frameworks for the professional and par-
ticipant representative stakeholders; these are identified
in Table 9 under Not Applicable.
In order to help shape the analysis and results, we cap-
tured key headlines for each stakeholder group by the topic
areas covered in the interviews to demonstrate the variabil-
ity and/or similarities between stakeholders. The initial ana-
lysis revealed nine themes but these were then merged to
five themes: security and transparency; inclusivity and en-
gagement; human interaction; obstacles and risks; and po-
tential benefits of digital tools (shown in Table 10).
Theme 1: Security and transparency
Although there was unified acceptance of the use of
digital tools, all participants felt that they should not lose
sight of the issues and barriers around security,
legitimacy and transparency of data. Concerns around
the risk of data breach, suitable digital platforms and
anonymization of data were key considerations and con-
cerns to all participants.
‘There was a fear … there still is a fear … where is it
going to, who is holding this information? … If you’re
throwing out an invitation you have to know where
you are throwing it.’ (ID5 – Ethics Committee
member)
For participant representatives, there was greater con-
cern about how and where data are stored and how to
legitimise the point of initial contact.
‘… I would Google the email address, which I do
quite frequently now, with all the GDPR stuff … I
would look to see if it was a bona fide email, and go
in via the Internet rather than something that has
perhaps been linked essentially … I think as long as
you know that it is a … it has got governance, I sup-
pose when you are looking at clinicaltrials.gov, you
know it is part of the government framework.’ (ID4 –
Participant representative)
Theme 2: Inclusivity and engagement
Adopting the use of digital tools across different types of
populations was considered essential for all participant
groups. This not only focused on the perspective of the
individual but also the availability and acceptance of
using a digital device, including using a digital interface
(e.g. downloading an application to a mobile device).
The key findings from stakeholder professionals mainly
focused on people’s ability to use digital tools and the
appropriateness for some participant groups.
‘Some patients, they’re quite happy having everything
emailed, others want telephone calls … its different
for everyone so I think you just have to be flexible.’
(ID10 – Practitioner in Primary Care)
‘Potential to exclude people based on their ability to
use these tools … you might exclude people who
Table 5 Number of digital retention tools that CTUs mentioned
they have experience of in relation to retention, broken down
by category
Retention tools n (%)
SMS / email reminders 17 (59)
Study websites 3 (10)
Apps and web-based data collection 3 (10)
Social media 2 (7)
Other – in-house 4 (14)
CTU Clinical Trials Unit
Table 6 Number of digital tools in relation to recruitment that
CTUs mentioned they have experience of, broken down by
category
Recruitment tools n (%)
Database tool (Clinical Practice Research Datalink [CPRD], in-
house built tool, disease registry)
10
(45)
Social media (e.g. Facebook, Twitter, YouTube) 6 (27)
Trial websites 4 (18)
ISRCTN, clinicaltrials.gov 1 (5)
Other – in-house 1 (5)
CTU Clinical Trials Unit, CPRD Clinical Practice Research Datalink
Table 7 Number of digital retention tools CTUs mentioned that
had impressed them, broken down by category
Retention tools n (%)
SMS / email reminders 10 (67)
Study websites 0 (0)
Apps and web-based data collection 0 (0)
Social media 1 (7)
Other – in-house 4 (18)
CTU Clinical Trials Unit
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don’t have a smart phone …’ (ID3-Practitioners in
Primary Care)
‘Approaching people by a different route is poten-
tially a way of providing information to people
that they wouldn’t otherwise be given through the
typical kind of health professionals’ route. It
opens up an avenue for actually getting greater
dissemination about research opportunities.’
(ID1 – Trialist)
The participant representatives were generally accepting
of digital tools, although they felt that careful consider-
ation is needed when applying these tools across differ-
ent participant groups. The consensus was more focused
on use of data, and accessibility to participate in clinical
trials.
‘I just think if it’s going to help someone else, then
they’re welcome to it … No, that doesn’t bother
me … I would be more worried about things like
Table 8 List of potential digital tools to support recruitment and retention tasks
Task Target Possible tools
Publicise a trial Recruiters (site and CTU trial staff) Social media, email campaign
Identify possible patients for a trial offline Recruiters (site staff only) Database screening (e.g. CPRD)
Trial eligibility checklist on trial website
Identify patients for trial during consultation Recruiters (site staff only) Automated flag based on EPR
Ensure patient really was eligible for trial when recruited Recruiter (site staff only) EPR database check on entry
Incentivise recruiters Recruiters (site and CTU trial staff) Automated league table, lottery for recruiters
Simplified trial recruitment workflow
Online patient information/video, etc.
Raise public awareness about trials in general Public / patients Social media, email campaigns
Help patients find a specific trial Public / patients clinicaltrials.gov, trial website; Google ads or
pop up on disease website
Improve public understanding of a specific trial Patients Trial website
eConsent video, animated patient information
leaflet
Web chat with trial nurse
App (software) providing tailored information for
patient
CPRD Clinical Practice Research Datalink, CTU Clinical Trials Unit, EPR electronic patient records
Table 9 Content analysis of responses from the five stakeholder groups











Interview framework topics ↓
Generic statements 3 3 3 3 NA 12
Benefit 2 2 0 3 4 11
Intended outcomes of digital
tools
1 0 0 1 NA 2
Acceptance NA NA NA NA 4 4
Challenges/barriers 2 3 3 3 4 15
Participant perspective 2 2 2 1 NA 9
Awareness of evidence 2 1 3 2 NA 8
Funding issues 2 1 0 2 1 6
Ethics 2 2 3 0 2 9
GDPR / Security 2 1 1 1 4 9
PPI 3 1 2 1 NA 7
Evidence 2 2 0 3 NA 7
Tools used 3 3 0 1 NA 7
Knowledge of digital tools NA NA NA NA 4 4
GDPR, NA not applicable, GDPR - General Data Protection Regulation, PPI - Patient and Public Involvement
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my bank account than, you know, someone might
know what things that I’ve had or what I’m
doing.’ (ID2 – Participant representative)
Theme 3: Human interaction
The trade-off between the use of digital tools and having
human interaction was an important consequence for
consideration when using these methods to recruit and
retain participants in trials.
‘Digital recruitment can kind of be seen as a some-
what arm’s length approach, as opposed to a face-
to-face discussion. And I’m not saying that you have
one without the other, but I have seen some research
that suggests people recruited digitally if you like,
whilst the recruitment was better the retention was
poorer than recruitment via a face-to-face meeting.’
(ID1 – Trialist)
However, it was felt by the majority of the participants
that as long as the appropriate ethical and legal frame-
works are adhered to, there is less risk involved and pro-
vides reassurance to those taking part in a trial.
‘I suppose the potential participants might be a bit
frightened of the new … once you stop to think about
it, they don’t worry, but I think the initial thing is …
this bit of a fear of the new … the cyber divide is
breaking down and even older people will be able to
embrace it.’ (ID4 – Ethics Committee member)
Theme 4: Obstacles and risks
For some stakeholder groups, it was felt that a range of
approaches and methods should be offered to potential
participants, rather than relying on the use of digital
tools alone. Therefore, providing flexibility and choice
about the use of multi-methods in order to recruit.
However, it was also noted how there needs to be some
recognition of the speed at which digital technology is
evolving and the risks associated to this for both partici-
pants and trialists.
‘I don’t think you could have total digital, and
maybe a freedom to say to the person if you need
contact … and maybe they just phone up, because
that is one to one as well isn’t it? And so having that
alongside?’ (ID01 – Participant representative)
‘ … The rapidity with which things become obsolete,
in terms of digital platforms, is frighteningly rapid. I
think that does complicate this space; it makes it
more difficult to identify what’s best practice and
then replicate it at an industrial scale.’ (ID11 –
Funder)
There was a clear distinction between stakeholders
about the value, benefit and influence of existing evi-
dence (or rather lack of this). Charities were more likely
to take an evidence-user driven approach, rather than
rely on existing academic evidence.
‘ … We tend to come at it from a “How does the
market behave when you ask it to do something?” ra-
ther than “We need evidence to do it” because this
isn’t trying to introduce a health intervention … re-
cruitment methods for lots of companies like banks
and other commercial organisations, there’s a lot to
learn from those, so we tend to come at it from that
angle … we work out what it is they want to do that
doesn’t rely on research evidence … they get back
from contributing to and that’s consumer behaviour.’
(ID12 – Funder)
A number of issues raised by the stakeholder groups fo-
cused on staffing issues and the level of expertise re-
quired with information technology, the potential cost of
developing and setting up of digital tools, the barriers of
understanding for funders and ethics committees, the
speed at which technologies are advancing and the rapid
uptake of usability (e.g. the risk of being obsolete) and
how the risk of technical issues can hinder recruitment
progression.
‘We want to wait for the evidence to grow, because
it’s quite early days I guess for whether multi-media
does enhance information and understanding of po-
tential participants.’ (ID7 – Ethics member)
‘Sometimes you drop functionality in your digital
tool in order to satisfy everybody … they definitely
don’t understand the different levels of security …
You’ll get lots of things where they don’t really
understand what’s more secure, what’s less secure.’
(ID2 – Trialist)
Theme 5: Potential benefits
The overall acceptance of digital technology was clear
across all stakeholder groups, despite the lack of or use
of evidence to support their use for recruitment and re-
tention of participants. The use of digital tools were seen
as having the potential to widen the reach of participant
engagement and provide the flexibility for participants to
complete data entry.
‘I can’t see any reason why you wouldn’t want to
store the data digitally. The data is going to end up
in an electronic format anyway.’ (ID3 – Participant
representative)
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‘People are not bothered about it. I think they’ve got
over the botheredliness of it all … it’s accepted that
digital tools are extremely useful and, in some in-
stance, the only way you’re going to get your likely
participants … I think we’re getting better at it.’ (ID5
– Ethics Committee member)
‘You’ve got to demonstrate that you’ve got the expertise
to handle the electronic aspect of your research … and
have people been offered a choice … the principles of
fair consent are the same whether its electronic or
face-to-face …’ (ID4 – Ethics Committee member)
Discussion
The findings from both CTU survey and qualitative in-
terviews demonstrate the potential role for digital tools
in the recruitment and retention of participants in clin-
ical trials. However, the potential benefits from using
digital tools are still relatively unknown, despite the fre-
quency of their use. This has important implications not
only for research participants and trialists but also for
funding organisations and medical research charities.
The cost of setting up and maintaining some digital
tools is expensive and this can have repercussions for
not only trialists but also funders of research. Given the
dearth of high-quality evidence to validate or support
the use of digital tools, it is imperative that the evidence
generated plays particular attention to the nuances par-
ticularly identified through the qualitative interviews that
‘not one size fits all’. There is also the need to appreciate
that although the Internet can be a potentially valuable
tool, there are unchartered ethical considerations for tri-
alists such as the security of personal data, given the
new GDPR [21]. Technology is also moving fast, which
can make it difficult to identify what is best for a par-
ticular group of participants.
As the literature suggests, high-quality evidence is
needed to determine the value of digital tools and their
potential. Despite this, some trials are already using
these technologies to improve trial recruitment and re-
tention with minimal understanding of their effective-
ness or appropriateness (lack of evidence to support
their use) [6, 9]. By further investigating the use of
digital tools for trial recruitment and retention, we will
be much better placed to understand their value and
benefit for future clinical health research. Only then can
we confidently advise on the wider use of digital tools by
trialists / researchers and the need for further primary
research. This evidence-based approach is critical to
counter the ‘apptimism’ (excessive optimism about apps
and other digital health tools) that has built up around
the use of digital tools in health services research [22].
Strengths and weaknesses of the study
The main strength of the study was the inclusion of a
broad spectrum of stakeholders, using mixed methods to
understand their position on the use and experience of
using digital tools for the recruitment to and retention
in clinical trials [23]. The CTU survey was able to collect
views from a range of CTU staff with different job roles.
The qualitative interviews comprised five stakeholder
groups, including research participant representation,
which provided an in-depth understanding from a range
of perspectives of how digital tools are viewed. This has
important implications for the development of digital
tools and their sustainability for use in trials; if partici-
pants are unwilling to, or do not see the authenticity /
legitimacy of the invitation to participate in a study,
problems with recruitment and retention will undoubt-
edly remain. By using an inductive approach, we were
able to gain a valuable insight into what matters to these
stakeholders, without influencing their perspective on
the use of digital tools.
Although not all CTUs took part in the survey, the re-
sponses received provided adequate coverage to begin
understanding the types of digital tools used and the
variation of their use. Extending the survey duration
may have resulted in a higher response rate, although we
cannot say with certainty that this would have been the
case and the funding was time limited. The qualitative
interviews were conducted with a small number of
stakeholders (three for each category, with four research
participant representatives) and yet the study achieved
its recruitment target. By not recruiting to the intended
focus group for the participant representative group, it
was clear that telephone interviews were the preferred
method for these individuals. This has important impli-
cations for future research, when considering the use of
Table 10 Summary of themes identified
Theme 1: Security and transparency
- Security and legitimacy of information and data [sharing]
- Efficiency and transparency of information and data
Theme 2: Inclusivity and engagement
- Equity and inclusion of populations
- Recognition of the ability / inability to use digital tools
Theme 3: Human interaction
- Trade-off between human face to face and digital tools
- Lose sight of human interface and the importance of face-to-face
connection
Theme 4: Obstacles and risks
- Obstacles preventing the use of digital tools (e.g. evidence, barriers,
solutions)
- Risk of technology overload
Theme 5: Potential benefits
- Unknown potential for the use of digital tools (e.g. evidence)
- Reducing the burden on participants (e.g. convenience, time)
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focus groups with participant representative groups.
There is a potential risk of bias due to the sample being
purposive and only being limited to randomised trials.
However, given the restricted timeframe for completion,
the findings from the qualitative interviews provided
preliminary data for further consideration.
Implications
To help fill the gaps in the evidence base we encourage
future research to consider conducting more defined
and specific systematic reviews on particular digital tools
commonly used by CTUs. Future primary research may
benefit from greater guidance to improve the evidence
base, including liaison with Trial Forge [24, 25], so that
assessment of promising digital tools can be evaluated
within the NIHR Study within a Trial (SWAT)
programme [26]. Possible topics might include: (1) a
randomised trial comparing email with social media for
recruitment in different age groups, studying the reach
across differing socioeconomic groups; and (2) further
Delphi research into appropriate tools for people with
different disease types and prevention versus treatment.
One implication for researchers in this area is that we
should study not only the various potential benefits of
these tools, but also the potential challenges they raise,
as documented in the qualitative study results.
Conclusion
Our study demonstrates the variety of digital tools being
used and how they are seen to be successful by trialists,
as well as noting the limited empirical evidence to sup-
port their use. Our examples of what constitutes a digital
tool (Table 8) will help to inform the NIHR and wider
research community about what is currently available
and help them identify potential tools to help with re-
cruitment to and retention within their studies.
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